Skip to main
MRUS
MRUS logo

Merus (MRUS) Stock Forecast & Price Target

Merus (MRUS) Analyst Ratings

Based on 19 analyst ratings
Strong Buy
Strong Buy 63%
Buy 32%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Merus NV is poised for a positive outlook due to its advancements in the clinical development of bispecific antibody therapeutics, particularly as preliminary data indicates that its pipeline candidates could exceed benchmarks established by historical therapies. The company has garnered FDA breakthrough therapy designation for multiple indications, which not only de-risks ongoing Phase 3 trials but also enhances its competitive positioning in the immuno-oncology market. Additionally, the encouraging efficacy signals from its therapeutics support the validity of its targeted mechanisms, potentially paving the way for first-to-market advantages in a rapidly evolving landscape.

Bears say

The analysis indicates that Merus NV faces significant challenges in visibility and predictability regarding the outcomes of its clinical trials, particularly with regards to the LiGeR-HN1 study and its Phase 2 updates, suggesting increased uncertainty surrounding its path to potential commercialization. Additionally, the company's reliance on a limited product pipeline, alongside risks associated with regulatory hurdles, emerging competition, and potential issues in meeting sales expectations, exacerbates concerns about its financial stability. Furthermore, the comparative weakness of the Phase 1/2 dataset for the "ficera" therapeutic raises red flags about future regulatory approvals, indicating that the company may not achieve the anticipated benefits from its developmental programs.

Merus (MRUS) has been analyzed by 19 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 32% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merus (MRUS) Forecast

Analysts have given Merus (MRUS) a Strong Buy based on their latest research and market trends.

According to 19 analysts, Merus (MRUS) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merus (MRUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.